SITC & Cancer Immunotherapy: When Vision Becomes Reality
SITC members lead the cancer immunotherapy revolution impacting the care of patients with cancer.
Sunday, November 8
Saturday, November 7
SITC 2015 Awardees
Congratulations to all SITC 2015 awardees! This year, SITC presented more than 60 awards to young investigators, members and luminaries in the field. Download the 30th Anniversary Award Ceremony booklet here.
Friday, November 6
Dr. Howard L. Kaufman on Impact of T-VEC FDA Approval via OncLive
Howard L. Kaufman, MD, FACS, Chief Surgical Officer, Associate Director for Clinical Science, Surgical Oncologist, Rutgers Cancer Institute, Society for Immunotherapy of Cancer (SITC) President, discusses the impact of the recent FDA approval of talimogene laherparepvec (T-VEC) for the treatment of melanoma lesions in the skin and lymph nodes. Read more.
Thursday, November 5
Dr. Stephen Grupp on Engineered Cell Therapy for the Treatment of Pediatric ALL via OncLive
Stephen Grupp, MD, PhD, director of translational research for the center for Childhood Cancer Research at The Children's Hospital of Philadelphia (CHOP) and medical director of the Stem Cell Laboratory at CHOP, discusses the use of engineered cell therapy for the treatment of Acute Lymphoblastic Leukemia (ALL) in children. Read more.
Wednesday, November 4
Journal for ImmunoTherapy of Cancer 30th Anniversary Annual Meeting Abstract Supplement
Access all accepted SITC 2015 abstracts here.